Sinja Taavitsainen
Sinja Taavitsainen
Doctoral researcher, Tampere University
Подтвержден адрес электронной почты в домене tuni.fi
Название
Процитировано
Процитировано
Год
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
2452018
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ...
The Lancet Oncology 20 (12), 1730-1739, 2019
1352019
Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer
E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ...
Clinical Cancer Research 26 (5), 1114-1125, 2020
282020
Interleukin 10 mutant zebrafish have an enhanced interferon gamma response and improved survival against a Mycobacterium marinum infection
SKE Harjula, MJT Ojanen, S Taavitsainen, M Nykter, M Rämet
Scientific reports 8 (1), 1-17, 2018
192018
Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer
S Taavitsainen, M Annala, E Ledet, K Beja, PJ Miller, M Moses, M Nykter, ...
JCO precision oncology 3, 1-9, 2019
182019
Frequent mutation of the FOXA1 untranslated region in prostate cancer
M Annala, S Taavitsainen, G Vandekerkhove, JVW Bacon, K Beja, KN Chi, ...
Communications biology 1 (1), 1-8, 2018
172018
Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer
C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ...
European Urology 78 (6), 834-844, 2020
122020
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ...
Annals of Oncology 32 (7), 896-905, 2021
82021
A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, ...
Annals of Oncology 29, viii271-viii272, 2018
82018
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ...
Nature communications 12 (1), 1-12, 2021
72021
HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two …
DJ Khalaf, IM Aragón, M Annala, R Lozano, S Taavitsainen, D Lorente, ...
Annals of Oncology 31 (9), 1186-1197, 2020
72020
Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy
DJ Woodcock, E Riabchenko, S Taavitsainen, M Kankainen, G Gundem, ...
Nature communications 11 (1), 1-13, 2020
62020
Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition
M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ...
Clinical Cancer Research 27 (16), 4610-4623, 2021
32021
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.
KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, ...
Journal of Clinical Oncology 37 (15_suppl), 5003-5003, 2019
32019
Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
E Warner, S Yip, M Annala, G Wang, A Angeles, A Beigi, E Schonlau, ...
CLINICAL CANCER RESEARCH 26 (11), 30-30, 2020
12020
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ...
Nature Communications 12 (1), 1-16, 2021
2021
Combined longitudinal clinical and autopsy phenomic assessment in lethal metastatic prostate cancer: recommendations for advancing precision medicine
J Jasu, T Tolonen, ES Antonarakis, H Beltran, S Halabi, MA Eisenberger, ...
European urology open science 30, 47-62, 2021
2021
Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity
K Ketola, H Kaljunen, S Taavitsainen, R Kaarijärvi, E Järvelä, BR Martin, ...
Cancer Research, 2021
2021
Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response
K Kukkonen, S Taavitsainen, L Huhtala, J Uusi-Makela, KJ Granberg, ...
Cancers 13 (13), 3325, 2021
2021
Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
CM Herberts, AJ Murtha, S Fu, G Wang, E Schonlau, A Gleave, S Yip, ...
CLINICAL CANCER RESEARCH 26 (11), 46-47, 2020
2020
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20